Compare Amphastar Pharmaceuticals Inc (AMPH) vs Suncor Energy Inc. (SU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Suncor Energy Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Suncor Energy Inc. trades at $59.31 (market cap $69.71B). The key difference: Suncor Energy Inc. is far larger — about 84.4× Amphastar Pharmaceuticals Inc's market cap, and Suncor Energy Inc. pays a 2.85% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SU | |
|---|---|---|
Market Cap | $826.08M | $69.71B |
Sector | Health | Energy |
52-Week High | $30.81 | $69.73 |
52-Week Low | $16.87 | $38.17 |
Enterprise Value | $1.22B | $77.84B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Suncor Energy (SU) trades at $59.25, up 1.3% today, with strong analyst support (74% buy ratings) and bullish technical signals. The stock shows solid fundamentals with a P/E of 15.99, net margin of 11.62%, and consistent dividend payments. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 results exceeded forecasts. Cash flow remains positive with $166M net inflow in 2025.
Outlook remains positive with expected revenue growth to $54.5B in 2026 and improving profit margins. Key risks include oil price volatility and operational challenges. The stock presents value opportunity with attractive valuation metrics and strong institutional support, though investors should monitor Q2 2026 earnings results against the $2.26 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
